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Abstract
Genomewide association studies (GWAS) and candidate-gene studies have implicated single-
nucleotide polymorphisms (SNPs) in at least 45 different genes as putative glioma risk factors.
Attempts to validate these associations have yielded variable results and few genetic risk factors
have been consistently replicated. We conducted a case-control study of Caucasian glioma cases
and controls from the University of California San Francisco (810 cases, 512 controls) and the
Mayo Clinic (852 cases, 789 controls) in an attempt to replicate previously reported genetic risk
factors for glioma. Sixty SNPs selected from the literature (eight from GWAS and 52 from
candidate-gene studies) were successfully genotyped on an Illumina custom genotyping panel.
Eight SNPs in/near seven different genes (TERT, EGFR, CCDC26, CDKN2A, PHLDB1, RTEL1,
TP53) were significantly associated with glioma risk in the combined dataset (P < 0.05), with all
associations in the same direction as in previous reports. Several SNP associations showed
considerable differences across histologic subtype. All eight successfully replicated associations
were first identified by GWAS, although none of the putative risk SNPs from candidate-gene
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studies was associated in the full case-control sample (all P values > 0.05). Although several
confirmed associations are located near genes long known to be involved in gliomagenesis (e.g.,
EGFR, CDKN2A, TP53), these associations were first discovered by the GWAS approach and are
in noncoding regions. These results highlight that the deficiencies of the candidate-gene approach
lay in selecting both appropriate genes and relevant SNPs within these genes.
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Introduction
Heritable susceptibility to glioma was originally suggested by the increased risk observed in
patients with an affected first-degree relative, and also by the association of glioma with
several well-defined Mendelian disorders (e.g., Neurofibromatosis Type 1, Lynch syndrome,
Li-Fraumeni syndrome) [Malmer et al., 2007]. Gliomagenesis is, however, a complex and
multifaceted process influenced by both heritable and somatic genetic variation. Studies of
glioma tumor DNA have found that mutations in the genes IDH1 and IDH2 occur in
approximately 50–80% of grades 2–3 glioma, but in < 10% of primary glioblastomas
[Christensen et al., 2010; Yan et al., 2009]. These mutations are associated with younger age
of onset and better survival among glioma patients, and are also associated with other
somatic genetic and epigenetic alterations [Hartmann et al., 2009].
Studies of constitutional DNA from glioma patients have implicated at least 44 different
genes in gliomagenesis. These investigations have mostly been candidate-gene studies,
which frequently examine genes involved in a biological pathway of interest, such as DNA
repair [Bethke et al., 2008c; Felini et al., 2007; Liu et al., 2007], apoptosis [Bethke et al.,
2008a; Rajaraman et al., 2007], or folate metabolism [Bethke et al., 2008b]. However,
robustly replicated risk genes have not emerged from these candidate studies and
inconsistent associations are the norm.
Genomewide association studies (GWAS) of glioma have been conducted in recent years,
identifying eight single-nucleotide polymorphisms (SNPs) in seven different genes which
are independently associated with glioma risk [Sanson et al., 2011; Shete et al., 2009; Stacey
et al., 2011; Wrensch et al., 2009]. The “hypothesis-free” GWAS approach has realized
greater success than the candidate-gene approach, at least in part because it is not gene-
centric. Indeed, across all the GWAS conducted to date for more than 500 diseases/traits,
most significantly associated SNPs have been found in noncoding regions of the genome
[Hindorff et al., 2009]. Furthermore, because of the lack of prior hypotheses, most GWAS
are designed to include a replication phase to minimize false positives. Despite the
shortcomings of the candidate-gene approach, such studies frequently evaluate well-
considered a priori hypotheses. Because several of the glioma risk genes identified through
GWAS had prior data indicating their potential involvement in gliomagenesis (i.e., TP53,
p15/CDKN2B, EGFR), there is strong rationale to attempt replication of putative glioma
risk loci appearing in the candidate-gene literature.
In order to assess the role of genetic variation at loci previously implicated in influencing
glioma risk, we conducted a case-control study of Caucasian glioma patients and ancestry-
matched controls. A total of 2,963 individuals recruited at The University of California, San
Francisco and the Mayo Clinic were genotyped on an Illumina GoldenGate (Illumina, San
Diego, CA) custom panel containing candidate SNPs selected from 28 previous
publications. In total, 61 candidate SNPs were assayed, including eight previous GWAS hits
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on chromosomes 5, 7 (two loci), 8, 9, 11, 17, and 20. We sought to replicate previously
detected SNP associations using a larger sample size than any of the candidate-gene studies,
and also to evaluate these associations within specific histologic subgroups.
Materials and Methods
Study Population
This study included European-ancestry glioma cases and controls from two collaborating
institutions: The University of California, San Francisco (810 cases, 512 controls) and the
Mayo Clinic (852 cases, 789 controls). All participating institutions received institutional
review board approval and informed consent was obtained from subjects. Patient
recruitment methods have been described in detail elsewhere [Jenkins et al., 2012]. Briefly,
UCSF cases and controls were taken from the San Francisco Bay Area Adult Glioma Study.
Cases aged 20 or older, diagnosed with histologically confirmed incident glioma were
recruited from the local population-based registry, the Northern California Rapid Case
Ascertainment program, and the UCSF Neuro-oncology clinic between 1997 and 2012.
Controls aged 20 years or older from the same residential area as cases were ascertained
through random digit dialing, had no history of brain tumor at time of recruitment, and were
frequency matched to population-based cases on age, sex, and ethnicity.
Mayo Clinic cases consisted of patients 18 years of age and older that had surgical resection
or biopsy of a glioma between 1989 and 2012. Cases were identified at diagnosis (for those
initially seen at the Mayo Clinic) or at the time of pathologic confirmation (for those initially
diagnosed elsewhere and subsequently treated at Mayo). The Mayo control group consisted
of consented individuals, 18 years of age and older that underwent a general medical
examination at the Mayo Clinic, and had no previous history of a brain tumor. Subject
characteristics, including histopathologic classification of glioma cases, are outlined in
Table 1. Pathology review was performed as previously described [Jenkins et al., 2012;
Wrensch et al., 2009].
SNP Selection
A Medline search was performed on September 1, 2011 to retrieve association studies
identifying at least one significantly associated glioma risk SNP using the following search
expression (glioma[Title/Abstract] OR glioblastoma[Title/Abstract] OR astrocytoma[Title/
Abstract] OR oligodendroglioma[Title/Abstract]) AND association[Title/Abstract] AND
(SNP[Title/Abstract] OR single nucleotide polymorphism). Additionally, the bibliographies
of selected articles were scanned to identify pertinent publications which the electronic
search may have missed. Results were not filtered by language. Only studies which assayed
SNPs were included because other variant types (e.g., microsatellites) are not amenable to
the genotyping platform used in our study. Manuscripts were scanned and eliminated from
further analysis as outlined in Supporting information Figure SI.
SNPs from 28 publications which investigated the role of inherited genetic variation in
influencing glioma risk were included, of which 4 studies were GWAS [Sanson et al., 2011;
Shete et al., 2009; Stacey et al., 2011; Wrensch et al., 2009] and 24 were candidate-gene
studies [Bethke et al., 2008a,b,c; Brenner et al., 2007; Caggana et al., 2001; Chang et al.,
2008; Chen et al., 2000; Dobbins et al., 2011; Dou et al., 2010; Felini et al., 2007; Liu et al.,
2009, 2007, 2008; Rajaraman et al., 2007; Ruan et al., 2011; Schwartzbaum et al., 2005,
2007, 2010; Semmler et al., 2006; Wang et al., 2010; Wiemels et al., 2007; Wiencke et al.,
2005; Wrensch et al., 2005; Yang et al., 2005]. Sample size, patient ethnicity, histological
inclusion criteria, and the study hypothesis of included studies are outlined in Table 2.
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From these studies, 61 SNPs, including eight identified in glioma GWAS, were selected for
replication analysis in our study sample. The remaining 53 SNPs were reported to be
associated with glioma risk in candidate-gene studies, with reported P values ranging from
1.45 × 10−4 to 0.042.
Genotyping
GoldenGate custom genotyping arrays were designed by Illumina (San Diego, CA).
Genotyping was performed by the Mayo Clinic Genotyping and UCSF Genome Center core
facilities as previously published [Jenkins et al., 2012]. Samples were submitted in 96-well
plates containing intra- and inter-plate replicates to ensure genotype reproducibility. All
cluster plots were visually inspected.
For both study sites, samples with genotyping call rate <95% were excluded from analysis.
SNPs with genotyping call rates <95% in any site were excluded from all analyses. To
exclude poorly genotyped SNPs, any SNP with a Hardy-Weinberg Equilibrium (HWE) P-
value < 0.001 in controls, stratified by site, was removed from further analyses.
Statistical Analysis of SNP Associations
Single SNP association statistics were calculated using logistic regression in Plink v1.07,
assuming a log-additive model [http://pngu.mgh.harvard.edu/purcell/plink/] [Purcell et al.,
2007]. The effect of individual SNPs on glioma risk was calculated in the full case-control
dataset using a logistic regression model adjusted for sex, age, and study site. Reported
associations are for an allelic additive model, adjusted for these covariates, where odds
ratios are for each additional copy of the minor allele. All P values are two-sided. SNP
associations were assessed in the full case-control sample, and also stratified by tumor
grade/histology (glioblastoma vs. controls, anaplastic astrocytoma vs. controls, grade 2
astrocytoma vs. controls, oligodendroglioma vs. controls, mixed oligoastrocytoma vs.
controls) and IDH mutation status of patient tumors (cases with IDH mutant tumors vs.
controls).
Of the 60 candidate SNPs for which replication was attempted, three were originally
reported on in a glioma GWAS published by our group [Wrensch et al., 2009]. That GWAS
case-control sample partially overlaps with the individuals reported on in this manuscript.
We therefore removed 433 individuals from the analysis of these three SNPs in order to
eliminate sample overlap with the previous GWAS report (i.e., N = 2,963 for 57 SNPs and
N = 2530 for 3 SNPs).
Assessment of IDH Mutation Status
UCSF tumor specimens were sequenced to identify IDH1 and IDH2 mutations using
previously described methods [Christensen et al., 2010]. Briefly, the region spanning the
R132 codon of IDH1 and the region spanning the R172 6 codon of IDH2 were amplified by
polymerase chain reaction with M13 tagged primers to facilitate amplification and
sequencing. Products were run on a 1.5% agarose gel and subsequently sequenced in both
directions at the UCSF Genomics Core Facility according to the manufacturer’s protocol.
Sequences were analyzed with Applied Biosystems Sequence Scanner Software v1.0. Mayo
Clinic tumor specimens were assayed for IDH1 mutations using pyrosequencing and IDH2
mutations using both pyrosequencing and Sanger sequencing as previously described [Kipp
et al., 2012].
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Results
After excluding samples with call rates <95%, 2,959 participants remained for analysis
(1,660 cases, 1,299 controls). After excluding SNPs that did not meet call-rate or HWE
thresholds, 60 SNPs remained for analysis.
In the combined analysis of all glioma tumor histologies, seven SNPs were associated with
case-control status at a P-value < 0.05. This included seven of the eight SNPs identified to
be associated with glioma risk in previous GWAS. The eighth SNP identified via GWAS,
rs498872 on chromosome 11, was associated only when analyses were restricted to the
oligodendroglioma, mixed oligoastrocytoma, or IDH mutant subgroups, consistent with
previous reports of the histologic specificity of this association (Table 3) [Jenkins, 2012].
For all eight SNPs, the direction of association in our data matches that in previous GWAS.
Many of the significantly associated SNPs in Table 3 show marked differences in
association across histologic subtypes. As previously reported, rs4295627 on chromosome 8
and rs498872 on chromosome 11 are more strongly associated with tumors having an
oligodendroglial component or an IDH mutation [Jenkins, 2012; Jenkins et al., 2011]. SNPs
in EGFR and CDKN2A, on the other hand, show weak associations with oligodendroglial
tumors but stronger associations with high-grade astrocytic tumors. SNPs in TERT, TP53,
and RTEL1 show only modest differences in effect size across histology strata and appear to
be more general glioma risk factors.
Of the 52 remaining successfully genotyped SNPs, all selected from the candidate-gene
literature, no significant associations were detected in analysis of the full case-control
dataset (all P values > 0.05, Supporting information Table SI). Associations stratified by
tumor histology and by IDH-mutation status can also be found in Supporting information
Table SI. We were able to determine the previously reported direction of association and
reference allele for 39 of these 52 SNPs. The direction of association reported in the
literature matched that observed in our data for just 13/39 (33%) of the putative risk SNPs
abstracted from the candidate-gene literature, compared with 50% expected by chance and
100% for SNPs identified by previous GWAS.
Discussion
The importance of performing robust SNP replication studies cannot be understated, as
additional samples help to validate purported genotype-phenotype correlations and extend
them to additional populations. We replicated associations at all eight glioma risk SNPs
originally identified by the GWAS method, attesting to the efficacy of this approach and its
ability to produce robust associations. Furthermore, the GWAS approach can identify
associated genes acting in biological pathways not previously known to influence disease
pathogenesis. Two such genes with relevance to glioma are involved in telomere elongation:
TERT and RTEL1 (rs2736100 and rs6010620, respectively). Before GWAS were
conducted, telomere function was not linked to gliomagenesis and as a result, this important
aspect of glioma biology remained unstudied.
In the case of glioma, TP53 and p16Ink4a (containing CDKN2A, CDKN2B, and ANRIL) are
obvious candidate loci based on the glioma-associated Mendelian syndromes resulting from
deletion of these regions. Inherited mutations in TP53 cause Li-Fraumeni syndrome (Online
Mendelian Inheritance in Man (OMIM): 151623) and inherited deletions of CDKN2A cause
familial melanoma-astrocytoma syndrome (OMIM: 155755). Additionally, the relevance of
EGFR to gliomagenesis has long been apparent, as it is commonly amplified in glioma
tumor samples [Wong et al., 1987]. Yet, significant and robustly replicated SNPs in TP53,
CDKN2B, and EGFR were first identified by GWAS, despite being preceded by a plethora
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of candidate-gene studies. Although the most obvious drawback of the candidate-gene
approach is that selection of relevant genes is limited by the current state of biological
knowledge, selecting the relevant SNPs within those genes can be a comparable challenge.
Of the eight significant SNPs identified through GWAS, none are located in coding regions
(two intergenic, four intronic, one 3′-UTR, one 5′-UTR). This is in stark contrast to the 53
SNPs identified by candidate-gene studies, nearly half of which are located in exons but
none of which were replicated. The impetus to identify coding variants of potential
functional relevance is understandable. However, researchers performing candidate-gene
studies in the future should recognize that genotyping such variants does not align with the
genetic paradigm recently revealed by GWAS: Namely, that common variants are associated
with common diseases, but such loci are often noncoding variants of a regulatory nature or
are manifestations of “synthetic associations” [Dickson et al., 2010]. Selecting SNPs to
genotype based on position within exons and predicted effect on protein function, as
opposed to their ability to tag haplotype blocks, appears to be a poor strategy for identifying
new associations given the results of the GWAS published to date.
The associations appearing in Supporting information Table SI can serve as a resource for
researchers interested in these particular genes or in performing meta-analyses of SNPs
potentially associated with glioma risk. The identification of constitutional genetic
polymorphisms associated with the development of glioma has brought us closer to
understanding the causal mechanisms underlying gliomagenesis. Additionally, excluding
erroneous associations generated by studies with immoderate Type 1 error rates helps to
focus research on more salient endeavors, such as fine-mapping of the confirmed risk loci.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Demographic and tumor histology characteristics of UCSF Adult Glioma Study and Mayo Clinic glioma cases
and controls used in the genetic association analyses
UCSF (N = 1322) Mayo Clinic (N = 1,641)
Casea Control Caseb Control
Sample size 810 512 852 789
Mean ± SD
Age 49.8 ± 14.4 57.9 ± 15.3 48.1 ± 14.4 49.8 ± 14.1
n (%)
Male 501 (61.9) 289 (56.4) 488 (57.3) 450 (57.0)
Glioblastoma 390 NA 330 NA
Anaplastic astro 104 NA 188 NA
Grade 2 astro 84 NA 65 NA
Mixed oligoastro 59 NA 166 NA
Oligodendroglioma 168 NA 98 NA
aNumbers by histologic type add to 805 because three astrocytomas were of indeterminate grade and two gliomas had no histology information.
bNumbers by histologic type add to 847 because five astrocytomas were of indeterminate grade.
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